120 related articles for article (PubMed ID: 23224939)
1. External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia.
Molica S; Giannarelli D; Gentile M; Cutrona G; Di Renzo N; Di Raimondo F; Neri A; Federico M; Ferrrarini M; Morabito F
Cancer; 2013 Mar; 119(6):1177-85. PubMed ID: 23224939
[TBL] [Abstract][Full Text] [Related]
2. The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis.
Molica S; Giannarelli D; Gentile M; Cutrona G; Di Renzo N; Di Raimondo F; Neri A; Federico M; Ferrarini M; Morabito F
Leuk Res; 2013 Aug; 37(8):943-7. PubMed ID: 23499499
[TBL] [Abstract][Full Text] [Related]
3. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.
Bulian P; Tarnani M; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; Deaglio S; D'Arena G; Efremov D; Marasca R; Lauria F; Gattei V; Gaidano G; Laurenti L
Hematol Oncol; 2011 Jun; 29(2):91-9. PubMed ID: 20669154
[TBL] [Abstract][Full Text] [Related]
4. Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.
Gentile M; Mauro FR; Rossi D; Vincelli I; Tripepi G; Recchia AG; De Stefano L; Campanelli M; Giannarelli D; Bossio S; Morabito L; Vigna E; Gaidano G; Foà R; Morabito F
Br J Haematol; 2014 Oct; 167(2):224-32. PubMed ID: 25041609
[TBL] [Abstract][Full Text] [Related]
5. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
6. Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival.
Molica S; Levato D; Dattilo A
Haematologica; 1999 Dec; 84(12):1094-9. PubMed ID: 10586211
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Gentile M; Cutrona G; Mosca L; Matis S; Fabris S; Lionetti M; Ilariucci F; Zupo S; Musolino C; Levato L; Molica S; Di Raimondo F; Vincelli I; Di Rienzo N; Pesce EA; Angrilli F; Federico M; Neri A; Ferrarini M; Morabito F
Am J Hematol; 2014 Jul; 89(7):743-50. PubMed ID: 24711230
[TBL] [Abstract][Full Text] [Related]
8. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
[TBL] [Abstract][Full Text] [Related]
9. Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model.
Molica S; Giannarelli D; Mirabelli R; Levato L; Russo A; Linardi M; Gentile M; Morabito F
Eur J Haematol; 2016 Jan; 96(1):72-7. PubMed ID: 25819739
[TBL] [Abstract][Full Text] [Related]
10. Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia.
Molica S; Digiesi G; Mirabelli R; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Morabito F; Neri A; Baldini L; Ferrarini M
Eur J Haematol; 2009 Sep; 83(3):208-14. PubMed ID: 19459926
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.
Shanafelt TD; Witzig TE; Fink SR; Jenkins RB; Paternoster SF; Smoley SA; Stockero KJ; Nast DM; Flynn HC; Tschumper RC; Geyer S; Zent CS; Call TG; Jelinek DF; Kay NE; Dewald GW
J Clin Oncol; 2006 Oct; 24(28):4634-41. PubMed ID: 17008705
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
Tsimberidou AM; O'Brien S; Kantarjian HM; Koller C; Hagemeister FB; Fayad L; Lerner S; Bueso-Ramos CE; Keating MJ
Cancer; 2006 Sep; 107(6):1294-302. PubMed ID: 16902984
[TBL] [Abstract][Full Text] [Related]
13. Validation of the postoperative nomogram for 12-year sarcoma-specific mortality.
Eilber FC; Brennan MF; Eilber FR; Dry SM; Singer S; Kattan MW
Cancer; 2004 Nov; 101(10):2270-5. PubMed ID: 15484214
[TBL] [Abstract][Full Text] [Related]
14. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Vacca A; Cuneo A; Ribatti D; Digiesi G
Eur J Haematol; 2004 Jul; 73(1):36-42. PubMed ID: 15182336
[TBL] [Abstract][Full Text] [Related]
15. External validation of a prognostic model predicting time of death after withdrawal of life support in neurocritical patients.
de Groot YJ; Lingsma HF; Bakker J; Gommers DA; Steyerberg E; Kompanje EJ
Crit Care Med; 2012 Jan; 40(1):233-8. PubMed ID: 21926586
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
17. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yang HI; Sherman M; Su J; Chen PJ; Liaw YF; Iloeje UH; Chen CJ
J Clin Oncol; 2010 May; 28(14):2437-44. PubMed ID: 20368541
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a prognostic nomogram for terminally ill cancer patients.
Feliu J; Jiménez-Gordo AM; Madero R; Rodríguez-Aizcorbe JR; Espinosa E; Castro J; Acedo JD; Martínez B; Alonso-Babarro A; Molina R; Cámara JC; García-Paredes ML; González-Barón M
J Natl Cancer Inst; 2011 Nov; 103(21):1613-20. PubMed ID: 21972226
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
